|
1
|
Lee ML, Tomsu K and Von Eschen KB:
Duration of survival for disseminated malignant melanoma: Results
of a meta-analysis. Melanoma Res. 10:81–92. 2000.PubMed/NCBI
|
|
2
|
Balch CM, Gershenwald JE, Soong SJ,
Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG,
Ding S, et al: Final version of 2009 AJCC melanoma staging and
classification. J Clin Oncol. 27:6199–6206. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Baderca F, Vincze D, Balica N and Solovan
C: Mucosal melanomas in the elderly: Challenging cases and review
of the literature. Clin Interv Aging. 9:929–937. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen H, Cai Y, Liu Y, He J, Hu Y, Xiao Q,
Hu W and Ding K: Incidence, surgical treatment, and prognosis of
anorectal melanoma from 1973 to 2011: A population-based SEER
analysis. Medicine (Baltimore). 95:e27702016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Arai T, Yanagisawa A, Kondo F, Aida J and
Takubo K: Clinicopathologic characteristics of esophageal primary
malignant melanoma. Esophagus. 13:17–24. 2016. View Article : Google Scholar
|
|
6
|
Cheung MC, Perez EA, Molina MA, Jin X,
Gutierrez JC, Franceschi D, Livingstone AS and Koniaris LG:
Defining the role of surgery for primary gastrointestinal tract
melanoma. J Gastrointest Surg. 12:731–738. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Akiyama M, Matsuda Y, Arai T and Saeki H:
Clinicopathological characteristics of malignant melanomas of the
skin and gastrointestinal tract. Oncol Lett. 16:2675–2681.
2018.PubMed/NCBI
|
|
8
|
Weber JS, D'Angelo SP, Minor D, Hodi FS,
Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH Jr, Lao CD,
et al: Nivolumab versus chemotherapy in patients with advanced
melanoma who progressed after anti-CTLA-4 treatment (CheckMate
037): A randomised, controlled, open-label, phase 3 trial. Lancet
Oncol. 16:375–384. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Freeman GJ, Long AJ, Iwai Y, Bourque K,
Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne
MC, et al: Engagement of the PD-1 immunoinhibitory receptor by a
novel B7 family member leads to negative regulation of lymphocyte
activation. J Exp Med. 192:1027–1034. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Topalian SL, Hodi FS, Brahmer JR,
Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD,
Sosman JA, Atkins MB, et al: Safety, activity, and immune
correlates of anti-PD-1 antibody in cancer. N Engl J Med.
366:2443–2454. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Scheel AH, Dietel M, Heukamp LC, Jöhrens
K, Kirchner T, Reu S, Rüschoff J, Schildhaus HU, Schirmacher P,
Tiemann M, et al: Harmonized PD-L1 immunohistochemistry for
pulmonary squamous-cell and adenocarcinomas. Mod Pathol.
29:1165–1172. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Snyder A, Makarov V, Merghoub T, Yuan J,
Zaretsky JM, Desrichard A, Walsh LA, Postow MA, Wong P, Ho TS, et
al: Genetic basis for clinical response to CTLA-4 blockade in
melanoma. N Engl J Med. 371:2189–2199. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gibney GT, Weiner LM and Atkins MB:
Predictive biomarkers for checkpoint inhibitor-based immunotherapy.
Lancet Oncol. 17:e542–e551. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hori S, Nomura T and Sakaguchi S: Control
of regulatory T cell development by the transcription factor Foxp3.
Science. 299:1057–1061. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen DS and Mellman I: Elements of cancer
immunity and the cancer-immune set point. Nature. 541:321–330.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Johnson DB, Estrada MV, Salgado R, Sanchez
V, Doxie DB, Opalenik SR, Vilgelm AE, Feld E, Johnson AS,
Greenplate AR, et al: Melanoma-specific MHC-II expression
represents a tumour-autonomous phenotype and predicts response to
anti-PD-1/PD-L1 therapy. Nat Commun. 7:105822016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Que Y, Xiao W, Guan YX, Liang Y, Yan SM,
Chen HY, Li QQ, Xu BS, Zhou ZW and Zhang X: PD-L1 expression is
associated with FOXP3+ regulatory T-cell infiltration of
soft tissue sarcoma and poor patient prognosis. J Cancer.
8:2018–2025. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pawelec G: Does patient age influence
anti-cancer immunity? Semin Immunopathol. 41:125–131. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kugel CH III, Douglass SM, Webster MR,
Kaur A, Liu Q, Yin X, Weiss SA, Darvishian F, Al-Rohil RN, Ndoye A,
et al: Age correlates with response to anti-PD1, reflecting
age-related differences in intratumoral effector and regulatory
T-cell populations. Clin Cancer Res. 24:5347–5356. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Espinosa E, Márquez-Rodas I, Soria A,
Berrocal A, Manzano JL, Gonzalez-Cao M and Martin-Algarra S;
Spanish Melanoma Group (GEM), : Predictive factors of response to
immunotherapy-a review from the Spanish Melanoma Group (GEM). Ann
Transl Med. 5:3892017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shang B and Liu Y, Jiang SJ and Liu Y:
Prognostic value of tumor-infiltrating FoxP3+ regulatory
T cells in cancers: A systematic review and meta-analysis. Sci Rep.
5:151792015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yun S, Park Y, Moon S, Ahn S, Lee K, Park
HJ, Lee HS, Choe G and Lee KS: Clinicopathological and prognostic
significance of programmed death ligand 1 expression in Korean
melanoma patients. J Cancer. 10:3070–3078. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Frydenlund N, Leone D, Yang S, Hoang MP,
Deng A, Hernandez-Perez M, Singh R, Biswas A, Yaar R and Mahalingam
M: Tumoral PD-L1 expression in desmoplastic melanoma is associated
with depth of invasion, tumor-infiltrating CD8 cytotoxic
lymphocytes and the mixed cytomorphological variant. Mod Pathol.
30:357–369. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kaunitz GJ, Cottrell TR, Lilo M, Muthappan
V, Esandrio J, Berry S, Xu H, Ogurtsova A, Anders RA, Fischer AH,
et al: Melanoma subtypes demonstrate distinct PD-L1 expression
profiles. Lab Invest. 97:1063–1071. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li Z, Dong P, Ren M, Song Y, Qian X, Yang
Y, Li S, Zhang X and Liu F: PD-L1 expression is associated with
tumor FOXP3(+) regulatory T-cell infiltration of breast cancer and
poor prognosis of patient. J Cancer. 7:784–793. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang HY, Wu XY, Zhang X, Yang XH, Long YK,
Feng YF and Wang F: Prevalence of NRAS mutation, PD-L1 expression
and amplification, and overall survival analysis in 36 primary
vaginal melanomas. Oncologist. Oct 2–2019.(Epub ahead of print).
doi: 10.1634/theoncologist2019-0148. View Article : Google Scholar
|
|
27
|
Koelblinger P, Emberger M, Drach M, Cheng
PF, Lang R, Levesque MP, Bauer JW and Dummer R: Increased tumour
cell PD-L1 expression, macrophage and dendritic cell infiltration
characterise the tumour microenvironment of ulcerated primary
melanomas. J Eur Acad Dermatol Venereol. 33:667–675. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Thierauf J, Veit JA, Affolter A, Bergmann
C, Grünow J, Laban S, Lennerz JK, Grünmüller L, Mauch C, Plinkert
PK, et al: Identification and clinical relevance of PD-L1
expression in primary mucosal malignant melanoma of the head and
neck. Melanoma Res. 25:503–509. 2015. View Article : Google Scholar : PubMed/NCBI
|
